Interest in annuity payment models is growing among companies and payers, but such models could be risk financial viability of small biotech companies. Companies and payers are increasingly exploring the idea of paying for expensive, game-changing pharmaceuticals in instalments over time rather than in one big initial lump sum. However, such models could lead small biotech companies to sell their assets to big pharma or stop them investing in certain high-risk ventures altogether, Walter Colasante explains in this interview with Scrip.
This article requires a subscription to view. Click here to learn more.
Disparities in screening and diagnosis for triple negative breast cancer
Gilead Sciences asked Charles River Associates and Tigerlily Foundation to examine the extent to which policies associated with triple negative breast cancer...